



October 20, 2015

The Honorable Mike Callton  
Chairman, House Committee on Health Policy  
Michigan House of Representatives  
Lansing, Michigan

Dear Chairman Callton & Members of the Committee:

Thank you for the opportunity to submit testimony on House Bill 4812. Express Scripts is a pharmacy benefits manager, and it is our mission to make drugs safer and more affordable for residents here in Michigan and the 85 million Americans nationwide for which we provide drug benefits.

When state legislatures started hearing testimony on the issue of biosimilars in 2013 -2014, Express Scripts stood on the opposite side of those supporting HB 4812 today. At that time, we stood at odds over whether this issue was timely, and whether any kind of notification would be necessary to protect patients. Since that time, Express Scripts has met with the brand pharmaceutical manufacturing community and attempted to broker an equitable solution on the issue of interchangeable biosimilars. The goals of those negotiations were to allow for a robust biosimilars market, while simultaneously protecting both patients and payers. Those negotiations were fruitful and compromise language was agreed upon.

HB 4812 represents that compromise. Specifically, I'd like to draw your attention to Section 17755(5)(A) which outlines the manner in which notification should occur if an interchangeable biological product is dispensed. Express Scripts fully supports this attempt to move our healthcare system to an electronic one, and believe that the language before you does just that.

If you have any questions, please do not hesitate to contact me.

Michael Harrold  
Senior Director, State Government Affairs  
Express Scripts  
One Express Way  
St. Louis, MO 63121

Phone: 314-684-6373

---